Menu Search
Equities

Santen Pharmaceutical Co Ltd

SZD:HAN

Santen Pharmaceutical Co Ltd

Actions
  • Price (EUR)10.10
  • Today's Change0.00 / 0.00%
  • Shares traded29.00
  • 1 Year change+22.42%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

  • Revenue in JPY (TTM)302.56bn
  • Net income in JPY26.13bn
  • Incorporated1925
  • Employees3.74k
  • Location
    Santen Pharmaceutical Co Ltd3-9-19, Shimo-Shinjo, Higashiyodogawa-kuOSAKA-SHI 530-8552JapanJPN
  • Phone+81 676648621
  • Fax+81 663593827
  • Websitehttps://www.santen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.